The World Health Organization (WHO) has temporarily called for suspension of Hydroxychloroquine (HCQ) trail on COVID patients stating that it may cause more harm than doing good. WHO Director-General Tedros Adhanom Ghebreyesus passed the statement in the wake of recently published The Lancet medical journal on May 22 which revealed that HCQ when used alone with a macrolide had higher mortality rate.
“The Executive Group of the Solidarity Trial, representing 10 of the participating countries, met on Saturday (May 23) and has agreed to review a comprehensive analysis and critical appraisal of all evidence available globally,” Tedros said in a virtual press conference.
“The Executive Group has implemented a temporary pause of the HCQ arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board. The other arms of the trial are continuing,” Tedros added. WHO started Solidarity Trial which is taken by 10 nation including India. Under this Solidarity Trial evaluation and efficacy of four drugs and combinations against COVID, which includes HCQ.
"The Executive Group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity Trial while the data is reviewed by the Data Safety Monitoring Board"-@DrTedros #COVID19
— World Health Organization (WHO) (@WHO) May 25, 2020
